Dr. Perl on the Outlook of FLT3 Inhibitors for AML

Alexander E. Perl, MD
Published Online: Thursday, Nov 02, 2017



Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

The first FLT3 inhibitor, midostaurin, is not potent enough against FLT3 and is more like a multikinase inhibitor. As a result, the newer FLT3 inhibitors are more potent and selective, explains Perl.

Perl says he is optimistic about patients with FLT3 mutations, as ongoing phase III trials have either completed or will soon complete accrual in relapsed or refractory patients with FLT3 mutations.


Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

The first FLT3 inhibitor, midostaurin, is not potent enough against FLT3 and is more like a multikinase inhibitor. As a result, the newer FLT3 inhibitors are more potent and selective, explains Perl.

Perl says he is optimistic about patients with FLT3 mutations, as ongoing phase III trials have either completed or will soon complete accrual in relapsed or refractory patients with FLT3 mutations.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x